Désolé, rien ne correspond à votre recherche. Réessayez avec des termes differents
Désolé, rien ne correspond à votre recherche. Réessayez avec des termes differents
En tant que prĂ©sident et associĂ© directeur de Jolt Capital, Jean Schmitt a dirigĂ© la vision de Jolt et son dĂ©veloppement depuis 2012. Lâimpulsion derriĂšre la fondation de Jolt a Ă©tĂ© la prise de conscience de Jean Schmitt que les meilleurs rendements ajustĂ©s au risque proviennent gĂ©nĂ©ralement des phases tardives et des cycles de croissance dans des entreprises qui ne font plus face au risque liĂ© Ă la technologie.
Avant de fonder Jolt Capital, Jean Schmitt Ă©tait Managing Partner chez Sofinnova Partners, dirigeant la pratique informatique en mettant l’accent sur les marchĂ©s des tĂ©lĂ©communications et du sans fil.
Avant sa carriĂšre d’investisseur, il a Ă©tĂ© PDG et fondateur de 4 sociĂ©tĂ©s avec des sorties rĂ©ussies, dont SLP InfoWare, qu’il a vendu Ă Gemplus (maintenant Gemalto, XPAR:GTO) en 2000 pour 60 millions de dollars, puis est devenu VP Telecom Solutions & Applications pour le plus grand groupe.
Jean Schmitt est diplĂŽmĂ© de TĂ©lĂ©com ParisTech et titulaire d’un DESS en Intelligence Artificielle. Il est professeur invitĂ© Ă Telecom ParisTech et Ă HEC Paris, ancien prĂ©sident de l’International Venture Club et membre du programme de mentorat Henkel X de Henkel.
Managing Director â Accenture Healthcare Technology France & BeNeLux
Laurent Stefani est directeur exĂ©cutif en charge des secteurs Life Sciences, MedTech, Health & Health Insurance chez Accenture oĂč il couvre lâensemble des engagements technologiques avec un focus particulier sur le Cloud, lâIntelligence artificielle et la transformation digitale.
DiplĂŽmĂ© de lâEcole Polytechnique, de lâEcole Nationale SupĂ©rieure des TĂ©lĂ©communications et de lâUniversidad PolitĂ©cnica de Madrid, Laurent Stefani a 18 ans d âexpĂ©rience en France et aux Etats-Unis dans lâindustrie de la santĂ©.
Managing Director – Accenture Healthcare Technology France & BeNeLux
Laurent Stefani is Executive Director in charge of Life Sciences, MedTech, Health & Health Insurance at Accenture where he covers all technology engagements with a particular focus on Cloud, Artificial Intelligence and Digital Transformation.
A graduate of the Ecole Polytechnique, the Ecole Nationale Supérieure des Télécommunications and the Universidad Politécnica de Madrid, Laurent Stefani has 18 years of experience in the healthcare industry in France and the United States.
Vincent Serra, 51 ans, docteur en Immunologie, est un dirigeant expĂ©rimentĂ© avec plus de 20 ans dâexpĂ©rience en biotechnologie, notamment dans le domaine de lâimmunothĂ©rapie. Il est lâauteur de plusieurs brevets et dâarticles dans des publications scientifiques avec comitĂ© de lecture, spĂ©cialisĂ©es dans le domaine des vaccins. Avant de rejoindre Neovacs en tant que directeur scientifique en janvier 2019, il a Ă©tĂ© responsable de lâinnovation externe chez Pierre Fabre, et directeur exĂ©cutif de son Fond dâinnovation. Vincent Serra a Ă©galement occupĂ© des fonctions de directeur scientifique, directeur gĂ©nĂ©ral et cofondateur de diffĂ©rentes sociĂ©tĂ©s de biotechnologie. Il a en outre mis en place de nombreux accords de licences durant sa carriĂšre, dĂ©veloppĂ© diffĂ©rents produits jusquâaux phases de dĂ©veloppement cliniques et participĂ© Ă la crĂ©ation et Ă lâintroduction en bourse de la sociĂ©tĂ© Abivax.
Vincent Serra, 51, PhD in Immunology, is a seasoned executive with over 20 years of experience in biotechnology, particularly in the field of immunotherapy. He is the author of several patents and articles in peer-reviewed scientific publications in the field of vaccines. Prior to joining Neovacs as Chief Scientific Officer in January 2019, he was Head of External Innovation at Pierre Fabre, and Executive Director of its Innovation Fund. Vincent Serra has also served as Chief Scientific Officer, Chief Executive Officer and co-founder of various biotechnology companies. In addition, he has established numerous licensing agreements during his career, developed various products through clinical development and participated in the creation and IPO of Abivax.
As President and Managing Partner of Jolt Capital, Jean Schmitt has led Jolt’s vision and development since 2012. The impetus behind the founding of Jolt was Jean Schmitt’s realization that the best risk-adjusted returns usually come from late-stage and growth cycles in companies that no longer face technology risk.
Prior to founding Jolt Capital, Jean Schmitt was a Managing Partner at Sofinnova Partners, leading the IT practice with a focus on the telecommunications and wireless markets.
Prior to his investment career, he was CEO and founder of 4 companies with successful exits, including SLP InfoWare, which he sold to Gemplus (now Gemalto, XPAR:GTO) in 2000 for $60 million, then became VP Telecom Solutions & Applications for the larger group.
Jean Schmitt is a graduate of TĂ©lĂ©com ParisTech and holds a DESS in Artificial Intelligence. He is a visiting professor at Telecom ParisTech and HEC Paris, former president of the International Venture Club and a member of Henkel’s Henkel X mentoring program.
AprĂšs une thĂšse doctorale dans le domaine de la Physique et 10 annĂ©es de recherche, Suat Topsu a obtenu un poste de Professeur des universitĂ©s dans le domaine de la Physique Quantique Ă lâUniversitĂ© de Paris-Saclay en 2008. En 2012 il a fondĂ© et dirigĂ© une entreprise basĂ©e sur une technologie de tĂ©lĂ©communication innovante issue de mon laboratoire, connue aujourdâhui sous le nom de LiFi. En 2018 il a rejoint en tant que PrĂ©sident ExĂ©cutif la Satt idfinnov (devenu Erganeo) pour aider Ă travers des investissements financiers dâautres technologies Deeptech Ă trouver leurs marchĂ©s. Il est Ă©galement administrateur de plusieurs entreprises innovantes et membres de fondations Ă but social ou environnemental.
After a doctoral thesis in Physics and 10 years of research, Suat Topsu obtained a position as University Professor in Quantum Physics at the University of Paris-Saclay in 2008. In 2012 he founded and ran a company based on an innovative telecommunication technology that came out of my lab, now known as LiFi. In 2018 he joined as Executive Chairman the Satt idfinnov (now Erganeo) to help through financial investments other Deeptech technologies to find their markets. He is also a director of several innovative companies and members of social and environmental foundations.
MĂ©decin gĂ©nĂ©raliste, mĂ©decin urgentiste et mĂ©decin du sport avec expĂ©rience des pratiques hospitaliĂšre et libĂ©rale. Tropisme fort pour lâinnovation en santĂ© avec passage Ă lâentrepreneuriat via Kamet, venture inventor and builder. Cofondateur et directeur mĂ©dical de Qare, solution et service de tĂ©lĂ©consultation B2C Ă destination de tous les patients afin dâamĂ©liorer lâaccĂšs Ă des soins de qualitĂ©, et permettre aux mĂ©decins de faire Ă©voluer leur pratique. Conviction forte du dimensionnement europĂ©en de la e-santĂ©, confirmĂ©e par lâacquisition en 2021 de Qare par HealthHero, leader europĂ©en de la-santĂ©. Board member de HealtHero France, vice-prĂ©sident du LeT (Les entreprises de TĂ©lĂ©mĂ©decine) et senior medical advisor pour des private equity et des venture capital.
General practitioner, emergency physician and sports physician with experience in hospital and private practice. Strong tropism for innovation in health with a move to entrepreneurship via Kamet, venture inventor and builder. Co-founder and medical director of Qare, a B2C teleconsultation solution and service for all patients in order to improve access to quality care and enable doctors to evolve their practice. Strong belief in the European dimension of e-health, confirmed by the acquisition in 2021 of Qare by HealthHero, the European leader in e-health. Board member of HealtHero France, vice-president of LeT (Les entreprises de Télémédecine) and senior medical advisor for private equity and venture capital.
Hugo BrugiĂšre is a graduate of the Saint-Cyr military academy and of Sciences Po Paris. A serial entrepreneur with more than twenty companies to his credit, he is particularly familiar with listed companies and restructuring/turnaround situations in which he has specialized for several years.
Hugo BrugiĂšre est diplĂŽmĂ© de l’Ă©cole spĂ©ciale militaire de Saint-Cyr et de Sciences Po Paris. Serial entrepreneur avec plus d’une vingtaine de sociĂ©tĂ©s Ă son actif, il connaĂźt particuliĂšrement bien les sociĂ©tĂ©s cotĂ©es et les situations de restructuration/retournement dans lesquelles il s’est spĂ©cialisĂ© depuis quelques annĂ©es.
Aged 56, François Miceli holds a degree in biological engineering from the University of Paris XII – UPEC, is an alumnus of INSEAD (Corporate Finance, EE) and an auditor at IHEDN (Institut des Hautes Etudes de DĂ©fense Nationale, promotion Chevalier Bayard). He began his career at CLONATEC, an OHF group listed on the second market (now Euronext Growth), one of the very first biotech companies in France, where he held the position of product manager at the international level.
At the end of 1990, he joined IDEXX Laboratories Incorporated, an American company listed on NASDAQ, where he successively held the positions of Director Europe, Asia, Africa and Middle East of a business unit, then Managing Director of the French subsidiary IDEXX France S.A. and finally Managing Director and member of the Board of Directors of the Italian subsidiary IDEXX Laboratories Italia. During all these years spent within IDEXX, François Miceli was a member of the European Executive Committee.
In 1998, he joined SYNBIOTICS, a spin-off of Laboratoires MERIAL, as Director of International Operations before participating in the creation of LMD Pharma, a biotechnology start-up alongside venture capital funds, Banexi Ventures, LCF Rothschild, Siparex and Sofimac Partners Capital Investissement.
From October 2003 to February 2011, François was Chairman of the Board of Directors of the IMAXIO group, which specializes in infectious diseases (vaccines) and oncology, based in Lyon and Clermont-Ferrand. Since February 2009, he was also President and CEO of AXCELL Biotechnologies, a subsidiary of Imaxio. Under his presidency, IMAXIO won successively the 3rd Deloitte Fast 50 – RhĂŽne-Alpes award in 2009 and the 2nd Deloitte Fast 50 – RhĂŽne-Alpes award in 2010. Within the framework of the IMAXIO group, François Miceli was also Manager of EDULIS Technologie, a holding company for the management of technological assets of the Imaxio group.
After having been a Venture Partner and a member of the investment committee, François MICELI fully joined the private equity firm SOFIMAC PARTNERS in 2012 as Senior Partner. Managing Partner of SOFIMAC INNOVATION, a management company with 400 million euros in innovation capital. The latter has just merged with UI Investissement in which François is Senior Associate Director for Innovation.
François is also a director of Exeliom Biosciences, Ixaltis, Eurekam, Diabeloop, Igyxos, Axoltis, Aptys Pharmaceuticals, Cellmade, Isorg, Precilens and Futuragaia.
He is also a member of the Board of Directors of the M2CARE gas pedal specialized in health and nutrition and was President of the SAS INSERM TRANSFERT INITIATIVE
Until May 2009, François Miceli chaired the Supervisory Board ofERYtech Pharma S.A . listed on Euronext and he is a former administrator of the SIMV (Syndicat de l’Industrie du MĂ©dicament VĂ©tĂ©rinaire). He is also AMF certified.
AgĂ© de 56 ans, diplĂŽmĂ© en gĂ©nie biologique Ă lâUniversitĂ© Paris XII â UPEC, ancien Ă©lĂšve de lâINSEAD (Corporate Finance, EE) et auditeur Ă lâIHEDN (Institut des Hautes Etudes de DĂ©fense Nationale, promotion Chevalier Bayard), François Miceli commence sa carriĂšre au sein de CLONATEC, groupe OHF cotĂ© au second marchĂ© (de nos jours Euronext Growth), lâune des toutes premiĂšres entreprises de biotechnologie en France dans laquelle il occupa les fonctions de chef de produits au niveau international.
Fin 1990, il intĂšgre la sociĂ©tĂ© amĂ©ricaine cotĂ©e au NASDAQ, IDEXX Laboratories Incorporated oĂč il occupa successivement les fonctions de Directeur Europe, Asie, Afrique et Moyen-Orient dâune business unit, puis Directeur GĂ©nĂ©ral de la filiale française IDEXX France S.A et enfin Administrateur DĂ©lĂ©guĂ© et membre du Conseil dâAdministration de la filiale italienne IDEXX Laboratories Italia. Au cours de toutes ces annĂ©es passĂ©es au sein IDEXX, François Miceli Ă©tait membre du ComitĂ© ExĂ©cutif Europe.
En 1998, il rejoint SYNBIOTICS, spin off des Laboratoires MERIAL comme Directeur des opérations internationales avant de participer à la création de LMD Pharma, start up de biotechnologie aux cÎtés des fonds de capital-risque, Banexi Ventures, LCF Rothschild, Siparex et Sofimac Partners Capital Investissement.
Dâoctobre 2003 Ă fĂ©vrier 2011, François occupa les fonctions de PrĂ©sident du Directoire du groupe IMAXIO spĂ©cialisĂ© dans les maladies infectieuses (vaccins) et lâoncologie basĂ©e Ă Lyon et Ă Clermont-Ferrand. Depuis fĂ©vrier 2009, il occupait Ă©galement les fonctions de PrĂ©sident et Directeur GĂ©nĂ©ral dâAXCELL Biotechnologies, filiale dâImaxio. Sous sa prĂ©sidence, IMAXIO a remportĂ© successivement le 3Ăšme prix Deloitte Fast 50 â RhĂŽne-Alpes en 2009 et le 2Ăšme prix Deloitte Fast 50 â RhĂŽne-Alpes en 2010. Dans le cadre du groupe IMAXIO, François Miceli a Ă©tĂ© Ă©galement GĂ©rant dâEDULIS Technologie, holding de gestion dâactifs technologiques du groupe Imaxio.
AprĂšs avoir Ă©tĂ© Venture Partner et membre du comitĂ© dâinvestissement, François MICELI a pleinement rejoint la sociĂ©tĂ© de capital-investissement SOFIMAC PARTNERS en 2012 comme Senior Partner. Directeur GĂ©nĂ©ral AssociĂ©Â de SOFIMAC INNOVATION, sociĂ©tĂ© de gestion gĂ©rant 400 Millions dâeuros dans le capital-innovation. Cette derniĂšre vient de fusionner avec UI Investissement dans laquelle François occuper les fonctions de Directeur AssociĂ© Senior pour lâInnovation.
François est également administrateur des sociétés Exeliom Biosciences, Ixaltis, Eurekam, Diabeloop, Igyxos, Axoltis, Aptys Pharmaceuticals, Cellmade, Isorg, Precilens et Futuragaia .
Â
Il est Ă©galement membre du Conseil dâadministration de lâaccĂ©lĂ©rateur M2CARE spĂ©cialisĂ© dans la santĂ© et la Nutrition et a Ă©tĂ© PrĂ©sident de la SAS INSERM TRANSFERT INITIATIVE
Â
Jusquâen mai 2009, François Miceli a prĂ©sidĂ© le Conseil de Surveillance dâERYtech Pharma S.A cotĂ©e sur Euronext et il est un ancien administrateur du SIMV (Syndicat de lâIndustrie du MĂ©dicament VĂ©tĂ©rinaire). Il est Ă©galement titulaire de la certification AMF.
LoĂŻc Poirier prĂ©sident directeur gĂ©nĂ©ral dâARCHOS, LOGIC INSTRUMENT et MEDICAL DEVICES VENTURE, a rejoint la sociĂ©tĂ© ARCHOS dĂ©but 2005. Le groupe a depuis commercialisĂ© plus de 20 millions de produits mobiles et rĂ©alisĂ© un chiffre dâaffaires cumulĂ© supĂ©rieur Ă 1.5Milliards ⏠sur les quinze derniĂšres annĂ©es.
Auparavant, il a occupĂ© le poste de Directeur Financier et OpĂ©rations, Monde, division Structure, chez lâĂ©quipementier Faurecia pendant plus de deux annĂ©es et restructurĂ© lâoutil industriel.
De 2000 Ă 2003, il a participĂ© au dĂ©veloppement du groupe CONSODATA, leader en CRM, de la gestion dâune croissance organique forte mais Ă©galement acteur de nombreuses acquisitions, aux Etats Unis, Canada et en Europe depuis Londres en qualitĂ© de CFO groupe et activement contribuĂ© Ă la cession au groupe Telecom Italia.
De 1992 Ă 2000, Loic a Ă©voluĂ© de Group Controller Ă Vice-PrĂ©sident Finance et OpĂ©rations au sein du groupe Packard Bell NEC et codirigĂ© notamment la filiale amĂ©ricaine NEC Solutions, en Californie. Au sein du groupe, il a eu lâopportunitĂ© dâimplanter des bureaux de ventes et usines en Asie, Afrique du Sud et IsraĂ«l de la conception Ă la commercialisation dâordinateur portables et autres Ă©quipements IT.
LoĂŻc Poirier est diplĂŽmĂ© de lâIpag Business School en France et de lâInsead (Executive Management Program).
LoĂŻc Poirier, CEO of ARCHOS, LOGIC INSTRUMENT and MEDICAL DEVICES VENTURE, joined ARCHOS in early 2005. Since then, the group has sold more than 20 million mobile products and achieved a cumulative turnover of more than âŹ1.5 billion over the last fifteen years.
Prior to that, he served as CFO and Operations Director, Worldwide, Structure Division, at the automotive supplier Faurecia for more than two years and restructured the company’s industrial facilities.
From 2000 to 2003, he participated in the development of the CONSODATA group, leader in CRM, managing a strong organic growth but also acting in numerous acquisitions, in the United States, Canada and in Europe from London as Group CFO and actively contributed to the sale to the Telecom Italia group.
From 1992 to 2000, Loic progressed from Group Controller to Vice President Finance and Operations within the Packard Bell NEC group and co-managed the American subsidiary NEC Solutions, in California. Within the group, he had the opportunity to set up sales offices and factories in Asia, South Africa and Israel from design to marketing of laptops and other IT equipment.
LoĂŻc Poirier is a graduate of Ipag Business School in France and of Insead (Executive Management Program).